Gene writing platform

The next step in
gene writing

Integra Therapeutic’s lead technology (FiCAT) is designed to be the next-generation of gene writers because it covers today’s main needs for developing efficient and safe cell and gene therapies:

Gene size

Precision

Stability

Size

Precision

Stability

Our technology combines proteins modified with CRISPR-Cas (find module) and PiggyBac transposase (cut-and-transfer module), allowing us to program the precise insertion of small and large fragments of DNA into the genome.
PiggyBac functional domains are engineered to provide increased on-target integration while reducing off-targets events.
FiCAT can be used for in vivo and ex vivo therapies. It also has the potential to tackle prevention and treatment of a wide range of oncological and autoimmune diseases.

VIDEO

PUBLICATIONS

Our gene writing platform has shown great promise in preclinical studies. Read the latest scientific publications and presentations:

Find and cut-and-transfer (FiCAT) mammalian genome engineering

Nature Communications (2021)

Pallarès-Masmitjà, M; Ivančić, D; Mir-Pedrol, J; Jaraba-Wallace, J; Tagliani, T; Oliva, B; Sánchez-Mejías, A; Güell, M.

Discovery and protein language model-guided design of hyperactive transposases

Nature Biotechnology (2025)

Ivančić, D; Agudelo, A; Lindstrom-Vautrin, J; Jaraba-Wallace, J; Gallo, M; Das, R; Ragel, A;Herrero-Vicente, J; Higueras, I; Billeci, F; Sanvicente-García, M; Petazzi, P; Ferruz, N; Sánchez-Mejías, A; Güell, M.